Physician profile
Xiaoying Deng
NPI 1649463647
$5,625.04
in general payments reported to CMS, 2019-2025
16 companies · $4,581 in 2025
The $4,581 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2021: $221 · 2022: $52.57 · 2023: $106 · 2024: $467 · 2025: $4,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,600 · Food and Beverage: $1,277 · Travel and Lodging: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,600.00 |
| Food and Beverage | $1,276.80 |
| Travel and Lodging | $277.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $4,269.29 | 2021-2025 | Filspari |
| Glaxosmithkline, LLC. | $226.49 | 2023-2024 | Benlysta |
| Mallinckrodt Enterprises LLC | $196.81 | 2019 | |
| Corcept Therapeutics | $147.22 | 2024-2025 | Korlym |
| Vantive US Healthcare LLC | $128.09 | 2025 | Renal - Chronic |
| Calliditas Therapeutics US INC. | $123.01 | 2024 | |
| Ardelyx, INC. | $108.28 | 2024 | Xphozah 30 Mg |
| Bard Peripheral Vascular, INC. | $91.75 | 2021-2022 | |
| Genzyme Corporation | $89.37 | 2025 | |
| Horizon Therapeutics Plc | $87.69 | 2021 | |
| Amgen INC. | $40.08 | 2021-2025 | Tavneos |
| Nxstage Medical, INC. | $39.14 | 2025 | Nxstage System One, Nxstage Pureflow Solution, Pureflow Sl |
| Otsuka America Pharmaceutical, INC. | $36.72 | 2022 | |
| Apellis Pharmaceuticals, INC. | $22.06 | 2025 | Empaveli |
| Baxter Healthcare | $19.04 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaoying Deng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.